Wegovy Pill Triggers Oral Obesity Drug Race as Eli Lilly Advances Orforglipron Toward Approval
The new oral version of semaglutide has reached high prescription numbers since its recent release. A data firm called…
-
-
FDA Approves Oral Semaglutide for Weight Loss, Cheaper Alternative to Injectable GLP-1 Drugs
In January 2026, the U.S. Food and Drug Administration approved an oral formulation of semaglutide for weight management. This…
-
After CagriSema Blow, Novo Reveals Data for Obesity ‘Triple’
The world of weight loss medicine reached a major turning point in February 2026. Novo Nordisk shared two big…
-
Do GLP-1 Pills Cause Hair Loss?
Starting a GLP-1 journey is a massive step toward taking back control of your health and feeling like yourself…
-
Eli Lilly Diversifies Portfolio and Manufacturing Beyond Obesity
Stepping into a new phase of corporate growth requires a very clear and bold vision. Eli Lilly recently committed…
-
GLP-1 Pills for BMI Over 30: Clinical Eligibility and Treatment Considerations
Taking the first step toward managing your weight is a huge milestone for your long-term health. For many, this…
-
Obesity and GLP-1 Pills: Clinical Differences Explained
The landscape of metabolic health is undergoing its most significant transformation since the discovery of insulin. For the past…
